EGFR blocker lapatinib inhibits the synthesis of matrix metalloproteinases from synovial fibroblasts

Creative Commons License

KEHRİBAR D. Y., Emmungil H., BAŞAK TÜRKMEN N., ÇİFTÇİ O., ŞALVA E., Ozgen M.

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.4, pp.1355-1361, 2022 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 52 Issue: 4
  • Publication Date: 2022
  • Doi Number: 10.55730/1300-0144.5442
  • Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.1355-1361
  • Keywords: Epidermal growth factor, lapatinib, matrix metalloproteinase, rheumatoid arthritis, synovial fibroblast, RHEUMATOID-ARTHRITIS, ANGIOGENESIS, CELLS, DESTRUCTION, TARGET, MODEL
  • Inonu University Affiliated: Yes

Abstract

Background/aim: Epidermal growth factor receptor (EGFR) family members and their associated ligands may be related to bone and joint destruction in rheumatoid arthritis. Matrix metalloproteinases are responsible for joint and bone tissue degradation. This study is intended to investigate the effect of epidermal growth factor receptor inhibition by lapatinib on the synthesis of matrix metalloproteinases in in vitro.